Imbruvica

Ibrutinib, the active ingredient in Imbruvica, is a Bruton tyrosine kinase (BTK) inhibitor presented as a tablet for oral use. It is indicated for several B‑cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, small lymphocytic lymphoma, and chronic graft‑versus‑host disease.

GNH USA supplies Imbruvica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global oncology needs.

Imbruvica targets B‑cell receptor signaling and is used in a range of B‑cell malignancies and related conditions.

- Chronic lymphocytic leukemia (CLL): improves progression‑free survival and disease control. - Mantle cell lymphoma (MCL): induces tumor regression and prolongs remission. - Waldenström macroglobulinemia: reduces IgM levels and disease burden. - Marginal zone lymphoma: achieves disease control and symptom relief. - Small lymphocytic lymphoma: prolongs remission duration. - Chronic graft‑versus‑host disease (cGVHD): alleviates disease manifestations and improves quality of life.

Ibrutinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: watery stools, usually mild to moderate. - Nausea: occasional upset stomach. - Fatigue: persistent tiredness. - Bruising or bleeding: easy bruising or nosebleeds.

Serious or Rare Side Effects: - Atrial fibrillation: irregular heart rhythm that may require medical attention. - Severe infections: opportunistic or bacterial infections requiring treatment. - Tumor lysis syndrome: rapid tumor breakdown leading to metabolic disturbances.

When prescribing Imbruvica, clinicians should observe several precautionary measures to minimize risk.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess infection risk: watch for signs of bacterial, fungal or viral infections. - Evaluate cardiac function: baseline ECG and periodic monitoring for arrhythmias. - Avoid strong CYP3A4 inhibitors: dose adjustment or alternative therapy may be needed. - Adjust in hepatic impairment: consider reduced dose in moderate liver dysfunction. - Store at ambient temperature: keep tablets in original container, protect from moisture and heat.

Ibrutinib may interact with other medicines that affect its metabolism or hemostasis.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase ibrutinib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): may enhance bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): increase risk of hemorrhage.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce drug levels and efficacy. - Proton pump inhibitors: may modestly affect absorption; monitor therapeutic response. - Live attenuated vaccines: consider timing as immunosuppression may affect vaccine efficacy.